259 related articles for article (PubMed ID: 27194477)
1. Functional Selectivity of CB2 Cannabinoid Receptor Ligands at a Canonical and Noncanonical Pathway.
Dhopeshwarkar A; Mackie K
J Pharmacol Exp Ther; 2016 Aug; 358(2):342-51. PubMed ID: 27194477
[TBL] [Abstract][Full Text] [Related]
2. Agonist-directed trafficking of response by endocannabinoids acting at CB2 receptors.
Shoemaker JL; Ruckle MB; Mayeux PR; Prather PL
J Pharmacol Exp Ther; 2005 Nov; 315(2):828-38. PubMed ID: 16081674
[TBL] [Abstract][Full Text] [Related]
3. Anandamide-mediated CB1/CB2 cannabinoid receptor--independent nitric oxide production in rabbit aortic endothelial cells.
McCollum L; Howlett AC; Mukhopadhyay S
J Pharmacol Exp Ther; 2007 Jun; 321(3):930-7. PubMed ID: 17379772
[TBL] [Abstract][Full Text] [Related]
4. Two Janus Cannabinoids That Are Both CB2 Agonists and CB1 Antagonists.
Dhopeshwarkar A; Murataeva N; Makriyannis A; Straiker A; Mackie K
J Pharmacol Exp Ther; 2017 Feb; 360(2):300-311. PubMed ID: 27927913
[TBL] [Abstract][Full Text] [Related]
5. The endocannabinoid noladin ether acts as a full agonist at human CB2 cannabinoid receptors.
Shoemaker JL; Joseph BK; Ruckle MB; Mayeux PR; Prather PL
J Pharmacol Exp Ther; 2005 Aug; 314(2):868-75. PubMed ID: 15901805
[TBL] [Abstract][Full Text] [Related]
6. Increase of mesenchymal stem cell migration by cannabidiol via activation of p42/44 MAPK.
Schmuhl E; Ramer R; Salamon A; Peters K; Hinz B
Biochem Pharmacol; 2014 Feb; 87(3):489-501. PubMed ID: 24304686
[TBL] [Abstract][Full Text] [Related]
7. Targeting cannabinoid receptor 2 (CB2) limits collagen production-An in vitro study in a primary culture of human fibroblasts.
Correia-Sá I; Carvalho C; A Machado V; Carvalho S; Serrão P; Marques M; Vieira-Coelho MA
Fundam Clin Pharmacol; 2022 Feb; 36(1):89-99. PubMed ID: 34259358
[TBL] [Abstract][Full Text] [Related]
8. Antinociceptive effects induced through the stimulation of spinal cannabinoid type 2 receptors in chronically inflamed mice.
Curto-Reyes V; Boto T; Hidalgo A; Menéndez L; Baamonde A
Eur J Pharmacol; 2011 Oct; 668(1-2):184-9. PubMed ID: 21771590
[TBL] [Abstract][Full Text] [Related]
9. Functional selectivity in CB(2) cannabinoid receptor signaling and regulation: implications for the therapeutic potential of CB(2) ligands.
Atwood BK; Wager-Miller J; Haskins C; Straiker A; Mackie K
Mol Pharmacol; 2012 Feb; 81(2):250-63. PubMed ID: 22064678
[TBL] [Abstract][Full Text] [Related]
10. Cannabinoid CB(2) receptor activation prevents bronchoconstriction and airway oedema in a model of gastro-oesophageal reflux.
Cui YY; D'Agostino B; Risse PA; Marrocco G; Naline E; Zhang Y; Chen HZ; Finance O; Rinaldi-Carmona M; Rossi F; Advenier C
Eur J Pharmacol; 2007 Nov; 573(1-3):206-13. PubMed ID: 17643417
[TBL] [Abstract][Full Text] [Related]
11. Analysis of tolerance and behavioral/physical dependence during chronic CB1 agonist treatment: effects of CB1 agonists, antagonists, and noncannabinoid drugs.
Desai RI; Thakur GA; Vemuri VK; Bajaj S; Makriyannis A; Bergman J
J Pharmacol Exp Ther; 2013 Feb; 344(2):319-28. PubMed ID: 23197773
[TBL] [Abstract][Full Text] [Related]
12. A novel cannabinoid peripheral cannabinoid receptor-selective inverse agonist blocks leukocyte recruitment in vivo.
Lunn CA; Fine JS; Rojas-Triana A; Jackson JV; Fan X; Kung TT; Gonsiorek W; Schwarz MA; Lavey B; Kozlowski JA; Narula SK; Lundell DJ; Hipkin RW; Bober LA
J Pharmacol Exp Ther; 2006 Feb; 316(2):780-8. PubMed ID: 16258021
[TBL] [Abstract][Full Text] [Related]
13. Inverse agonist properties of N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2, 4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide HCl (SR141716A) and 1-(2-chlorophenyl)-4-cyano-5-(4-methoxyphenyl)-1H-pyrazole-3-carboxyl ic acid phenylamide (CP-272871) for the CB(1) cannabinoid receptor.
Meschler JP; Kraichely DM; Wilken GH; Howlett AC
Biochem Pharmacol; 2000 Nov; 60(9):1315-23. PubMed ID: 11008125
[TBL] [Abstract][Full Text] [Related]
14. Cannabinoids activate mesolimbic dopamine neurons by an action on cannabinoid CB1 receptors.
Gessa GL; Melis M; Muntoni AL; Diana M
Eur J Pharmacol; 1998 Jan; 341(1):39-44. PubMed ID: 9489854
[TBL] [Abstract][Full Text] [Related]
15. Cannabinoid-mediated elevation of intracellular calcium: a structure-activity relationship.
Rao GK; Kaminski NE
J Pharmacol Exp Ther; 2006 May; 317(2):820-9. PubMed ID: 16436496
[TBL] [Abstract][Full Text] [Related]
16. Species comparison and pharmacological characterization of rat and human CB2 cannabinoid receptors.
Mukherjee S; Adams M; Whiteaker K; Daza A; Kage K; Cassar S; Meyer M; Yao BB
Eur J Pharmacol; 2004 Nov; 505(1-3):1-9. PubMed ID: 15556131
[TBL] [Abstract][Full Text] [Related]
17. Characterization of cannabinoid agonists and apparent pA2 analysis of cannabinoid antagonists in rhesus monkeys discriminating Delta9-tetrahydrocannabinol.
McMahon LR
J Pharmacol Exp Ther; 2006 Dec; 319(3):1211-8. PubMed ID: 16943255
[TBL] [Abstract][Full Text] [Related]
18. AB-CHMINACA, AB-PINACA, and FUBIMINA: Affinity and Potency of Novel Synthetic Cannabinoids in Producing Δ9-Tetrahydrocannabinol-Like Effects in Mice.
Wiley JL; Marusich JA; Lefever TW; Antonazzo KR; Wallgren MT; Cortes RA; Patel PR; Grabenauer M; Moore KN; Thomas BF
J Pharmacol Exp Ther; 2015 Sep; 354(3):328-39. PubMed ID: 26105953
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of the role of nicotinic acetylcholine receptor subtypes and cannabinoid system in the discriminative stimulus effects of nicotine in rats.
Zaniewska M; McCreary AC; Przegaliński E; Filip M
Eur J Pharmacol; 2006 Jul; 540(1-3):96-106. PubMed ID: 16730696
[TBL] [Abstract][Full Text] [Related]
20. Constitutive activity of cannabinoid-2 (CB2) receptors plays an essential role in the protean agonism of (+)AM1241 and L768242.
Mancini I; Brusa R; Quadrato G; Foglia C; Scandroglio P; Silverman LS; Tulshian D; Reggiani A; Beltramo M
Br J Pharmacol; 2009 Sep; 158(1):382-91. PubMed ID: 19552692
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
